KRAS-mutant colorectal cancer cell lines cause a prothrombotic state through the upregulation of thrombin: experimental study
- Duogang Xu 1,2, Changkang Liao 1,2, Jing Tan 1,2
- Duogang Xu 1,2, Changkang Liao 1,2, Jing Tan 1,2
- 1Department of General Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming.
- 2Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, China.
- 0Department of General Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.KRAS-mutant colorectal cancer cells increase platelet aggregation and thrombin expression, contributing to a prothrombotic state. This cellular hypercoagulability is linked to poor prognosis in colorectal cancer patients.
Area Of Science
- Oncology
- Hematology
- Molecular Biology
Background
- Colorectal cancer (CRC) prognosis is linked to KRAS genotype and a prothrombotic state.
- Hypercoagulability and cancer-related thrombosis are significant poor prognostic factors in CRC.
- Cellular-level confirmation of the KRAS-CRC prothrombotic correlation is lacking.
Purpose Of The Study
- To assess platelet aggregation rate induced by CRC cells with varying KRAS genotypes.
- To evaluate thrombin expression in CRC cells under different KRAS statuses.
- To explore the association between KRAS genotype and hypercoagulability at the cellular level.
Main Methods
- Platelet aggregation rate assays were performed.
- Western blotting analyzed thrombin expression.
- Four CRC cell lines (RKO, HCT116, SW480, SW620) with different KRAS genotypes were utilized.
- Tissue factor (FVIIa/TF) and thrombin inhibitors were used to investigate pathways.
Main Results
- KRAS-mutant CRC cells significantly increased maximal platelet aggregation (34.7%-63.8%).
- Metastatic SW620 cells showed higher aggregation rates than primary SW480 cells.
- RKO cells exhibited lower thrombin expression compared to other KRAS-mutant lines.
- Thrombin inhibitors more significantly reduced platelet aggregation in KRAS-mutant cells.
Conclusions
- KRAS-mutant CRC cell lines demonstrate increased hypercoagulability.
- Upregulated thrombin expression, primarily via the TF-thrombin pathway, drives this prothrombotic state.
- KRAS genotype influences cellular prothrombotic potential in colorectal cancer.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

